Daxor (NASDAQ:DXR – Get Free Report) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 20th. Analysts expect Daxor to announce earnings of ($0.11) per share and revenue of $1.90 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 28, 2026 at 4:00 PM ET.
Daxor Trading Up 0.9%
NASDAQ DXR opened at $10.29 on Wednesday. The stock has a 50-day simple moving average of $10.35 and a 200 day simple moving average of $10.70. Daxor has a 12 month low of $8.56 and a 12 month high of $14.76.
Institutional Trading of Daxor
An institutional investor recently bought a new stake in Daxor stock. Osaic Holdings Inc. bought a new position in shares of Daxor Corporation (NASDAQ:DXR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor at the end of the most recent quarter. Institutional investors own 1.34% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Report on DXR
About Daxor
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Read More
- Five stocks we like better than Daxor
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
